Peptide-Linked Bivalent Nanobody Constructs as Positive Allosteric Modulators of the Calcium-Sensing Receptor.
- 1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
We previously developed nanobodies acting as positive allosteric modulators (PAMs) of the calcium-sensing receptor (CaSR). Here, we sought to develop more potent CaSR modulators by creating bivalent nanobody constructs using 'tail-to-head' peptide-linker conjugation. The constructs were functionally characterized at CaSR in HEK293 cells in a Ca²⁺ mobilization assay. Homobivalent Nb4-Nb4 and Nb10-Nb10 constructs with linkers comprising 3, 5, 6 or 9 GGGG(S/T) repeats all displayed CaSR PAM potencies comparable with those exhibited by their monovalent counterparts. Likewise, five heterobivalent nanobodies combining Nb4, Nb10, Nb11, Nb36 or Nb37 through [GGGG(S/T)]₉ linkers exhibited PAM potencies similar to that of the monovalent version of the first (N-terminal) nanobody in the respective constructs. This prompted us to examine the functional properties of [GGGG(S/T)]₉-linked constructs combining Nb4 and the mGluR5-selective nanobody PAM Nb43mGlu5. Nb4-L9-Nb43mGlu5 displayed slightly increased CaSR PAM potency relative to Nb4, whereas Nb43mGlu5-L9-Nb4 exhibited ~40- and ~10-fold reduced potency compared with Nb4-L9-Nb43mGlu5 and Nb4, respectively. The findings indicate that 'tail-to-head' conjugation markedly reduces CaSR binding affinity of the second (C-terminal) nanobody and likely explains the lack of synergistic enhancement of PAM potency in the bivalent constructs. Thus, the suitability of tail-to-head linker conjugation of nanobodies is context dependent, governed by how the nanobody engages its target and by whether the linker perturbs these interactions.
Related
- Engineering a bivalent anti-CsGRP78 nanobody via CDR grafting: in silico design and cytotoxic validation
- Positive Allosteric Modulation of mGlu and Muscarinic Receptors Differentially Regulate Nitric Oxide-Dependent Signaling in a Scopolamine-Induced Model of Cognitive Impairment
- The α2‐Subunit Preferring GABA Positive Allosteric Modulator, N‐Desmethyl‐Clobazam in Peripheral Neuropathic Pain Patients: Results of a Phase IIa Randomised Placebo‐Controlled Ascending Dose Study
- Discovery of GluA3 preferring AMPA receptor positive allosteric modulator BRD3290
- Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer
BibTeX
@article{nabipour2026peptidelinked,
title = {{Peptide-Linked Bivalent Nanobody Constructs as Positive Allosteric Modulators of the Calcium-Sensing Receptor.}},
author = {Mahdis Nabipour and Charlotte Hagen Skadhauge and Line Juel Rasmussen and Hans Bräuner-Osborne and Jesper M Mathiesen and Anders A Jensen},
journal = {Basic \& clinical pharmacology \& toxicology},
year = {2026},
month = oct,
doi = {10.1111/bcpt.70320},
url = {https://europepmc.org/article/MED/42951375},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Peptide-Linked Bivalent Nanobody Constructs as Positive Allosteric Modulators of the Calcium-Sensing Receptor.
AU - Mahdis Nabipour
AU - Charlotte Hagen Skadhauge
AU - Line Juel Rasmussen
AU - Hans Bräuner-Osborne
AU - Jesper M Mathiesen
AU - Anders A Jensen
PY - 2026
DA - 2026/10/28
JO - Basic & clinical pharmacology & toxicology
DO - 10.1111/bcpt.70320
UR - https://europepmc.org/article/MED/42951375
AB - We previously developed nanobodies acting as positive allosteric modulators (PAMs) of the calcium-sensing receptor (CaSR). Here, we sought to develop more potent CaSR modulators by creating bivalent nanobody constructs using 'tail-to-head' peptide-linker conjugation. The constructs were functionally characterized at CaSR in HEK293 cells in a Ca²⁺ mobilization assay. Homobivalent Nb4-Nb4 and Nb10-Nb10 constructs with linkers comprising 3, 5, 6 or 9 GGGG(S/T) repeats all displayed CaSR PAM potencies comparable with those exhibited by their monovalent counterparts. Likewise, five heterobivalent nanobodies combining Nb4, Nb10, Nb11, Nb36 or Nb37 through [GGGG(S/T)]₉ linkers exhibited PAM potencies similar to that of the monovalent version of the first (N-terminal) nanobody in the respective constructs. This prompted us to examine the functional properties of [GGGG(S/T)]₉-linked constructs combining Nb4 and the mGluR5-selective nanobody PAM Nb43mGlu5. Nb4-L9-Nb43mGlu5 displayed slightly increased CaSR PAM potency relative to Nb4, whereas Nb43mGlu5-L9-Nb4 exhibited ~40- and ~10-fold reduced potency compared with Nb4-L9-Nb43mGlu5 and Nb4, respectively. The findings indicate that 'tail-to-head' conjugation markedly reduces CaSR binding affinity of the second (C-terminal) nanobody and likely explains the lack of synergistic enhancement of PAM potency in the bivalent constructs. Thus, the suitability of tail-to-head linker conjugation of nanobodies is context dependent, governed by how the nanobody engages its target and by whether the linker perturbs these interactions.
SN - 1742-7835
SN - 1742-7843
ER -